Core Viewpoint - The Sixth Biomanufacturing Industry Conference is set to take place on December 2 in Guangming District, Shenzhen, aiming to promote the deep integration of technological and industrial innovation for high-quality development in the biomanufacturing sector [1] Group 1: Event Overview - The conference is guided by the Chinese Society of Biotechnology and co-hosted by the Guangming District People's Government, Shenzhen Advanced Technology Research Institute, National Biomanufacturing Industry Innovation Center, and Shenzhen National High-tech Industry Innovation Center [1] - The event aims to gather high-quality resources and establish a professional, authoritative, and well-known industry brand conference [1] Group 2: Policy and Development Initiatives - The conference will release the "Several Regulations on Promoting the Innovative Development of the Synthetic Biology Industry" and municipal industrial policies to inject new momentum into the biomanufacturing industry [1] - These initiatives will clarify support paths for nurturing and create a favorable environment for collaboration among industry, academia, research, and capital [1] Group 3: Achievements and Announcements - Platforms such as the Future Food Cooperation Center and Shenzhen Synthetic Biology Industry Base will be inaugurated during the conference [1] - The "China Biomanufacturing Industry White Paper" and the National Biomanufacturing Insight System will be launched for the first time [1] - The conference will also feature the inaugural ceremony for the first batch of enterprises entering the National Biomanufacturing Industry Innovation Center, along with the collective unveiling of the "Top Ten New Products of 2025" [1]

Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly ...

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 （按首字母排序，排名不分先后， 嘉宾单位或头衔为参加往期活动时信息，或有改变 ） 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家 ...

Financial Data and Key Metrics Changes - As of December 31, 2024, cash, cash equivalents, and investment-grade securities increased to approximately $9.3 million from $7.3 million as of December 31, 2023 [35] - Revenue for the year ended December 31, 2024, rose to approximately $3.495 million compared to $2.899 million the previous year, driven by license revenue and enzyme sales [35][36] - The net loss for the year ended December 31, 2024, was approximately $5.809 million or $0.20 per share, compared to a net loss of $6.795 million or $0.24 per share for the previous year [39] Business Line Data and Key Metrics Changes - The company emphasized strong revenue performance from milestone and license payments totaling $1.9 million, focusing on products that do not require human or animal clinical trials for commercialization [8] - Recombinant human serum albumin (RHSA) is on track for commercial launch in 2025, with significant progress in the commercialization of several cell culture media components [14][52] - The dairy enzyme portfolio achieved a productivity milestone of $425,000, with a commercial launch anticipated in late 2025 [18] Market Data and Key Metrics Changes - The human albumin market is approximately $5.6 billion and is expected to grow at double digits per year, driven by increased vaccine production [106] - The DNase I and DNA ligase market is around $900 million, also growing at nearly double digits annually [106] - The non-animal dairy proteins market is valued at $26 billion, indicating significant opportunities for products like alpha-lactalbumin and lactoferrin [107] Company Strategy and Development Direction - The company is focused on near-term product commercialization and technology licensing, with a dual-track strategy of commercializing non-pharmaceutical products while building a robust biopharmaceutical pipeline [9][10] - Partnerships with organizations like CEPI and the Gates Foundation are aimed at accelerating the development and adoption of the C1 platform for vaccines and treatments [11][26] - The company is committed to delivering sustainable value to shareholders and partners through a growing pipeline and strong collaborations [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's strategic focus on product commercialization and technology licensing, positioning it to capitalize on emerging opportunities [7] - The management highlighted the importance of ongoing partnerships and funding initiatives to support long-term innovation and market presence [25][29] - The company is seeing increased interest in its platforms and technology, indicating a positive outlook for future revenue generation [50] Other Important Information - The company received a $4.5 million grant from CEPI to support the development of recombinant protein vaccines using the C1 platform, with Dyadic expected to receive $2.4 million of this amount [25][40] - The company is also advancing its pipeline of innovations in both animal and human health, demonstrating the versatility of the C1 platform [29] Q&A Session Summary Question: Can you explain the Gates Foundation and CEPI grants and their significance? - Management confirmed ongoing interest from both organizations and highlighted the importance of these grants in advancing the C1 platform and driving innovation [45][46] Question: What is the status of albumin commercialization? - Management indicated that they are on track for commercialization in early 2025, emphasizing the need for product validation and quality assurance [52][56] Question: Can you clarify the components of research and development revenue? - Management noted that 80% of R&D expenses are covered by external funding, which supports the development of the C1 platform [61] Question: What is the market size opportunity for various products? - Management provided insights into the market sizes for human albumin, DNase I, and non-animal dairy proteins, highlighting significant growth potential in these areas [106][107] Question: What is the status of the work done in South Africa? - Management mentioned that the focus has shifted to animal health vaccines, with ongoing development and potential clinical studies expected by the end of the year [119][120]